KRAS and non-small cell lung carcinoma: A study of the impact of STK11 and/or KEAP1 mutation on benefit to immunotherapy in KRAS mutant NSCLC found KEAP1 co-mutation had shorter OS (p = 0.006), while STK11 co-mutation did not have an impact on OS (p = 0.3), with authors concluding, KEAP1 was a predictive factor in metastatic KRAS-mutated NSCLC, treated with immunotherapy [85].